Patents by Inventor Eric A. Button

Eric A. Button has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150361479
    Abstract: Described herein is a method for determining the disease state in a patient using combined mean glucose measurements and 1,5-anhydroglucitol to identify individuals at risk for developing diabetes. The ratio of mean glucose measurements to 1,5-anhydroglucitol correlates significantly better to maximal levels of postmeal glucose levels and related measurements, than mean glucose measurements or 1,5-anhydroglucitol correlate independently.
    Type: Application
    Filed: August 26, 2015
    Publication date: December 17, 2015
    Inventors: Eric A Button, Robert Scott Foster
  • Publication number: 20130260403
    Abstract: Described herein is a method for determining the disease state in a patient using combined mean glucose measurements and 1,5-anhydroglucitol to identify individuals at risk for developing diabetes. The ratio of mean glucose measurements to 1,5-anhydroglucitol correlates significantly better to maximal levels of postmeal glucose levels and related measurements, than mean glucose measurements or 1,5-anhydroglucitol correlate independently.
    Type: Application
    Filed: October 19, 2011
    Publication date: October 3, 2013
    Inventors: Eric A. Button, Robert Scott Foster
  • Patent number: 8178312
    Abstract: The invention is a method of measuring blood glucose excursions in general, and postprandial hyperglycemia in diabetic patients in particular, by the 1,5-anhydroglucitol assay (1,5-AG) or A1C/1,5-AG assay combination. 1,5-AG levels and percent changes of 1,5-AG levels in short period are indicative of differing postmeal glucose levels in moderately-controlled diabetic patients with similar A1C levels. Thereby 1,5-AG assay is useful to identify diabetic patients who may be at risk for cardiovascular complications which would not be identifiable by A1C levels alone. Furthermore, ratios of A1C divided by 1,5-AG in each patient are superior indicators to 1,5-AG levels.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: May 15, 2012
    Assignees: Nippon Kayaku Kabushiki Kaisha, Toyota Tsusho America, Inc.
    Inventors: John B. Buse, Kathleen Dungan, Steven D. Wittlin, Eric A. Button, Shuhei Kato, Toshio Tanabe
  • Publication number: 20100047762
    Abstract: HbA1c measurement is a critical component of diabetes management; however, a key limitation of HbA1c as a measure of glycemia is the lack of timeliness—it does not detect underlying blood glucose excursion levels in moderately controlled diabetic patients (HbA1c<8) as it is a measurement of mean glucose levels over the longer-term. HbA1c also averages both hypo- and hyperglycemia over two to three months; therefore, it does not adequately reflect improvements in post-prandial hyperglycemia. 1,5-AG is also a marker of glycemic control over a shorter one to two week timeframe, but with a different mechanism than HbA1c. Given the unique biological and physiological characteristics of 1,5-AG, it is sensitive to acute and transient episodes of hyper-glycemia and is, therefore, a better indicator of glucose excursions. Peptidyl diabetic drugs such as pramlintide and exenatide have unique mechanisms of action and the glycemic effects of these drugs are not adequately shown by HbA1c.
    Type: Application
    Filed: March 20, 2008
    Publication date: February 25, 2010
    Applicants: NIPPON KAYAKU KABUSHIKI KAISHA, TOYOTA TSUSHO AMERICA, INC.
    Inventors: Eric A. Button, Hirotaka Ishibashi, R. Scott Foster, Toshio Tanabe
  • Publication number: 20080187943
    Abstract: The invention is a method of measuring blood glucose excursions in general, and postprandial hyperglycemia in diabetic patients in particular, by the 1,5-anhydroglucitol assay (1,5-AG) or A1C/1,5-AG assay combination. 1,5-AG levels and percent changes of 1,5-AG levels in short period are indicative of differing postmeal glucose levels in moderately-controlled diabetic patients with similar A1C levels. Thereby 1,5-AG assay is useful to identify diabetic patients who may be at risk for cardiovascular complications which would not be identifiable by A1C levels alone. Furthermore, ratios of A1C divided by 1,5-AG in each patient are superior indicators to 1,5-AG levels.
    Type: Application
    Filed: April 21, 2006
    Publication date: August 7, 2008
    Applicants: Nippon Kayaku Kabushiki Kisha, Toyota Tsusho America Inc.
    Inventors: John B. Buse, Kathleen Dungan, Steven D. Wittlin, Eric A. Button, Shuhei Kato, Toshio Tanabe